

Bibliography: Mucositis

Blijlevens NNA, McCann S, Bacon P, et al. Prospective Oral Mucositis Audit (POMA): occurrence and consequences of severe oral mucositis in high dose melphalan and BEAM conditioning. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 46.

Hunter A, Mahendra P, Wilson K, et al. A randomised, double-blind, placebo-controlled, multicentre trial of ATL-104, a swallowable mouthwash, in patients with oral mucositis following peripheral blood stem cell transplantation. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 45.

Isitt J, Murphy BA, Beaumont JL, et al. Oral mucositis-related morbidity and resource utilization in a prospective study of head and neck cancer patients. Oral Mucositis Study Group. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 5539.

Murphy BA, Beaumont JL, Isitt J, et al. Patient-reported mouth and throat soreness and medical resource use in a prospective observational study of head and neck cancer patients. Presented at the 18th Annual Symposium of the Multinational Association of Supportive Care in Cancer; June 22–24, 2006; Toronto, Canada. Abstract 16-106.

Nasilowska-Adamska B, Rzepecki P, Manko J, et al. The significance of palifermin (Kepivance) in reduction of oral mucositis incidence and acute graft-versus-host disease in patients with hematological diseases undergoing HSCT. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 2965.

Oster G, Vera-Llonch M, Ford C. Duration of ulcerative mucositis and outcomes of autologous (AU) hematopoietic stem cell transplantation (HSCT) following high-dose melphalan (MP) conditioning for multiple myeloma (MM). Presented at the 2006 Meeting of the American Society for Blood and Marrow Transplantation; February 16–20, 2006; Honolulu, Hawaii. Abstract 274.

Schuster MW, Anaissie E, Hurd D, et al. Final analysis of the phase II, randomized, double-blind, placebo-controlled trial of single-dose velafermin (CG53135-05) for the prevention of oral mucositis. Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology; June 2–6, 2006; Atlanta, Georgia. Abstract 6537.

Shea TC, Kewalramani T, Mun Y, Jayne G, Dreiling LK. Evaluation of single-dose palifermin to reduce oral mucositis in fractionated total-body irradiation and high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Presented at the 48th Annual Meeting of the American Society of Hematology; December 9–12, 2006; Orlando, Florida. Abstract 3073.

Sonis S, Vera-Llonch M, Ford C, Lu J, Khazanov I, Oster G. Duration of ulcerative mucositis (OM) and outcomes of allogeneic (AL) hematopoietic stem cell transplantation (HSCT) in patients with hematologic malignancies. Presented at the 2006 Meeting of the American Society for Blood and Marrow Transplantation; February 16–20, 2006; Honolulu, Hawaii. Abstract 56.

Sonis S, Keefe D, Elting L, et al. Burden of illness and economic impact of mucosal injury in solid tumor—a multinational prospective observational study design. Presented at the 18th Annual Symposium of the Multinational Association of Supportive Care in Cancer; June 22–24, 2006; Toronto, Canada. Abstract 16-101.

Vera-Llonch M, Sonis ST, Keefe D, et al. Identifying potential mucositis-related infection resource use in solid tumor cancer patients. Presented at the 31st Congress of the European Society for Medical Oncology; September 29–October 3, 2006; Istanbul, Turkey. Abstract 9890.

Vera-Llonch M, Sonis ST, Edelsberg J, Oster G, Isitt J, Mayne T. Identifying potential mucositis cost drivers in solid tumor cancer patients. Presented at the 48th Annual Meeting of the American Society of Therapeutic Radiology and Oncology; November 5–9, 2006; Philadelphia, Pa. Abstract 2560.